168 related articles for article (PubMed ID: 6366617)
1. [Effects of nandrolone decanoate on bone mineral content and intestinal absorption of calcium].
Nuti R; Righi GA; Turchetti V; Vattimo A
Minerva Med; 1984 Jan; 75(3-4):109-13. PubMed ID: 6366617
[TBL] [Abstract][Full Text] [Related]
2. [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].
Gennari C; Agnusdei D; Gonnelli S
Minerva Endocrinol; 1989; 14(1):69-74. PubMed ID: 2659955
[TBL] [Abstract][Full Text] [Related]
3. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study.
Gennari C; AgnusDei D; Gonnelli S; Nardi P
Maturitas; 1989 Sep; 11(3):187-97. PubMed ID: 2687645
[TBL] [Abstract][Full Text] [Related]
4. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?
Johansen JS; Hassager C; Pødenphant J; Riis BJ; Hartwell D; Thomsen K; Christiansen C
Bone Miner; 1989 Apr; 6(1):77-86. PubMed ID: 2665884
[TBL] [Abstract][Full Text] [Related]
5. Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic postmenopausal women.
Need AG; Morris HA; Hartley TF; Horowitz M; Nordin BE
Calcif Tissue Int; 1987 Jul; 41(1):7-10. PubMed ID: 3113703
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study.
Geusens P; Dequeker J
Bone Miner; 1986 Sep; 1(4):347-57. PubMed ID: 3333018
[TBL] [Abstract][Full Text] [Related]
7. A controlled trial of nandrolone decanoate in the treatment of rheumatoid arthritis in postmenopausal women.
Bird HA; Burkinshaw L; Pearson D; Atkinson PJ; Leatham PA; Hill J; Raven A; Wright V
Ann Rheum Dis; 1987 Mar; 46(3):237-43. PubMed ID: 3555359
[TBL] [Abstract][Full Text] [Related]
8. Effects of nandrolone decanoate on bone mass in established osteoporosis.
Passeri M; Pedrazzoni M; Pioli G; Butturini L; Ruys AH; Cortenraad MG
Maturitas; 1993 Nov; 17(3):211-9. PubMed ID: 8133796
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions.
Geusens P; Dequeker J; Verstraeten A; Nijs J; Van Holsbeeck M
Maturitas; 1986 Dec; 8(4):281-9. PubMed ID: 3574141
[TBL] [Abstract][Full Text] [Related]
10. Characterization of bone mineral composition in the proximal tibia of cynomolgus monkeys: effect of ovariectomy and nandrolone decanoate treatment.
Huang RY; Miller LM; Carlson CS; Chance MR
Bone; 2002 Mar; 30(3):492-7. PubMed ID: 11882463
[TBL] [Abstract][Full Text] [Related]
11. Lack of influence of the anabolic steroid nandrolondecanoate on bone metabolism.
Bijlsma JW; Duursma SA; Bosch R; Huber O
Acta Endocrinol (Copenh); 1982 Sep; 101(1):140-3. PubMed ID: 7124288
[TBL] [Abstract][Full Text] [Related]
12. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis.
Need AG; Horowitz M; Morris HA; Walker CJ; Nordin BE
Clin Orthop Relat Res; 1987 Dec; (225):273-8. PubMed ID: 3677513
[TBL] [Abstract][Full Text] [Related]
13. Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis.
Need AG; Horowitz M; Walker CJ; Chatterton BE; Chapman IC; Nordin BE
Bone; 1989; 10(1):3-6. PubMed ID: 2736154
[TBL] [Abstract][Full Text] [Related]
14. Double-blind placebo--controlled trial of nandrolone decanoate in postmenopausal osteoporosis.
Chhaparwal M; Saraf ML
Indian J Med Sci; 1998 Jun; 52(6):236-8. PubMed ID: 9849033
[No Abstract] [Full Text] [Related]
15. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy.
Hassager C; Jensen LT; Pødenphant J; Thomsen K; Christiansen C
Calcif Tissue Int; 1994 Jan; 54(1):30-3. PubMed ID: 8118750
[TBL] [Abstract][Full Text] [Related]
16. Effects of Nandrolone and TGF-beta1 in growing rabbits with osteopenia induced by over-supplementation of calcium and vitamin D3.
Aithal HP; Kinjavdekar P; Amarpal ; Pawde AM; Singh GR; Pattanaik AK; Varshney VP; Goswami TK; Setia HC
Vet Res Commun; 2009 Apr; 33(4):331-43. PubMed ID: 18949570
[TBL] [Abstract][Full Text] [Related]
17. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis.
Geusens P
Clin Rheumatol; 1995 Sep; 14 Suppl 3():32-9. PubMed ID: 8846659
[TBL] [Abstract][Full Text] [Related]
18. The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: the effect of nandrolone decanoate and female sex hormones.
Hassager C; Jensen LT; Johansen JS; Riis BJ; Melkko J; Pødenphant J; Risteli L; Christiansen C; Risteli J
Metabolism; 1991 Feb; 40(2):205-8. PubMed ID: 1988778
[TBL] [Abstract][Full Text] [Related]
19. Nandrolone decanoate for men with osteoporosis.
Hamdy RC; Moore SW; Whalen KE; Landy C
Am J Ther; 1998 Mar; 5(2):89-95. PubMed ID: 10099043
[TBL] [Abstract][Full Text] [Related]
20. Nandrolone decanoate treatment of post-menopausal osteoporosis for 2 years and effects of withdrawal.
Hassager C; Riis BJ; Pødenphant J; Christiansen C
Maturitas; 1989 Dec; 11(4):305-17. PubMed ID: 2693918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]